sorafenib and Emesis
sorafenib has been researched along with Emesis in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Berardi, R; Burattini, L; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Muzzonigro, G; Pantano, F; Santini, D; Santoni, M | 1 |
| Ganten, TM; Gotthardt, D; Jaeger, D; Koehler, C; Koschny, R; Stremmel, W | 1 |
Reviews
1 review(s) available for sorafenib and Emesis
| Article | Year |
|---|---|
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Topics: Adverse Drug Reaction Reporting Systems; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Incidence; Indazoles; Indoles; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vomiting | 2014 |
Other Studies
1 other study(ies) available for sorafenib and Emesis
| Article | Year |
|---|---|
Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Female; Follow-Up Studies; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Nausea; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Skin Diseases; Sorafenib; Survival Rate; Treatment Outcome; Vomiting | 2013 |